Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 9
Therapeutics Development 10
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 10
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 11
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 12
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 19
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 21
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 22
ACROVIS biostructures GmbH 22
Adrenomed AG 23
Am-Pharma B.V. 24
Angion Biomedica Corp. 25
Bolder Biotechnology, Inc. 26
Cellmid Limited 27
DiaMedica Inc. 28
Digna Biotech, S.L. 29
F. Hoffmann-La Roche Ltd. 30
G1 Therapeutics, Inc. 31
Hadasit Medical Research Services & Development Ltd 32
Kringle Pharma, Inc. 33
NephroGenex, Inc. 34
Noorik Biopharmaceuticals AG 35
Nyken BV 36
Opsona Therapeutics Ltd. 37
Quark Pharmaceuticals, Inc. 38
STATegics, Inc. 39
Thrasos, Inc. 40
Torrent Pharmaceuticals Limited 41
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
adrecizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BB-3 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BBT-030 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BBT-045 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CAB-101 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
cardiotrophin-1 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CXA-10 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DM-199 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HYPER-IL-6 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
KP-100IT - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MTP-131 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
N-003 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NOXD-21 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NYK-1341 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
OPN-305 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Pyridoxamine Dihydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
QPI-1002 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
R-190 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Recombinant Human Alkaline Phosphatase - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RO-6839328 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule to Activate Heat Shock Protein 70 (Hsp70) for Delayed Graft Function - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules for Acute Renal Failure - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
STSE-15 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
THR-184 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TRC-160334 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates 90
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 102
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 103
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 104
Featured News & Press Releases 104
Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury 104
Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury 104
Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury 105
Jul 01, 2014: Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients 106
May 01, 2014: Complexa Initiates First Clinical Trial of CXA-10 for Acute Kidney Injury 106
Mar 26, 2014: AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury 107
Feb 04, 2014: FDA Grants Thrasos Fast Track Designation for THR-184 in Acute Kidney Injury 107
Jan 28, 2014: American Journal of Kidney Disease publishes review article of Alkaline Phosphatase 108
Nov 08, 2013: AM-Pharma Presents Positive Data from recAP Preclinical Study at ASN Meeting 108
Sep 23, 2013: AM-Pharma Returns to Clinic with Phase I Trial of New Recombinant Human Alkaline Phosphatase to Treat Acute Kidney Injury 109
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 111
Disclaimer 111
List Of Tables
List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2015 10
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ACROVIS biostructures GmbH, H1 2015 22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H1 2015 23
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H1 2015 24
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H1 2015 25
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Bolder Biotechnology, Inc., H1 2015 26
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H1 2015 27
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H1 2015 28
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H1 2015 29
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 30
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H1 2015 31
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 32
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H1 2015 33
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H1 2015 34
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H1 2015 35
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H1 2015 36
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Opsona Therapeutics Ltd., H1 2015 37
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 38
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H1 2015 39
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos, Inc., H1 2015 40
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 41
Assessment by Monotherapy Products, H1 2015 42
Number of Products by Stage and Target, H1 2015 44
Number of Products by Stage and Mechanism of Action, H1 2015 46
Number of Products by Stage and Route of Administration, H1 2015 48
Number of Products by Stage and Molecule Type, H1 2015 50
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H1 2015 90
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2015 102
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2015 103
List Of Figures
List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2015 10
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 42
Number of Products by Top 10 Targets, H1 2015 43
Number of Products by Stage and Top 10 Targets, H1 2015 43
Number of Products by Top 10 Mechanism of Actions, H1 2015 45
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46
Number of Products by Top 10 Routes of Administration, H1 2015 47
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 48
Number of Products by Top 10 Molecule Types, H1 2015 49
Number of Products by Stage and Top 10 Molecule Types, H1 2015 50
